Mobile App

Google Play Apple Store
What does it take to start an expert PH referral center and become a clinical investigator?
AMA/ANCC/ACPE Activity
The Pulmonary Hypertension Association (PHA)-Accredited PH Care Centers (PHCC) program began in late 2011 with the goal to raise the overall quality of care and improve outcomes in patients with this life-threatening disease. Accreditation is based on a center’s overall commitment to PH patients, breadth of health care professionals involved and scope of services provided. Two types of centers will be accredited: Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP). Both will have demonstrated a commitment to providing expert-level care based on published consensus guidelines. PHCCs have the opportunity to enroll PH patients into the Pulmonary Hypertension Association Registry (PHAR) patient registry to evaluate trends and practice patterns to determine which treatments work best. Moreover, in the past two decades, research has vastly improved the understanding of the pathophysiology, diagnosis, and treatment of PAH. While no therapies have been approved to target new mechanisms of action in more than 15 years, multiple phase 2 and phase 3 clinical trials of novel therapies are underway. Therapeutic trials represent the front line of clinical progress, and becoming a clinical trial investigator in PH can further help deliver more life-changing therapies to patients with PH who need them.

This AMA/ANCC/ACPE accredited, on-demand video addresses some key questions on accredited PH Care Centers and what it takes to become a clinical trial investigator.
Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.





R. James White, MD, PhD R. James White, MD, PhD
Professor of Medicine, Pharmacology & Physiology
University of Rochester Medical Center

20
Supported by independent educational grants from United Therapeutics, a public benefit company; Bayer U.S.; and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson

Launch Date: December 4, 2023
Release Date: December 4, 2023
Expiration Date: November 30, 2024

November 30, 2024
Mini Module
7657
PAH.What'sNewDoc_WebBanner(1150).gif
False
Pulmonology

CookieConsent

Change Settings